August 22, 2014 Robert Sikorski, M.D., Ph.D. 18316 Tapwood Road Boyds, MD 20841 Dear Bob, (February 24th, 2017)
We remain very pleased with the prospect of your joining our team at FivePrime and have worked with our Compensation Committee to extend to you this revised offer of employment (enhanced stock option award and mortgage assistance) with Five Prime Therapeutics, Inc. as Vice President, Global Clinical Development, reporting directly to me. As a key member of the management team, you would be a member of the Executive Committee.
Executive Transition and Severance Benefits Agreement (March 11th, 2016)
This Executive Transition and Severance Benefits Agreement (this "Agreement"), entered into between Julie Hambleton, M.D., ("Executive") and Five Prime Therapeutics, Inc. (the "Company"), sets forth the terms for Executive's termination of employment with the Company, in accordance with that certain Executive Severance Benefits Agreement between Executive and the Company dated December 3, 2012 ("Benefits Agreement") and as otherwise provided in this Agreement. Capitalized terms used in this Agreement, not otherwise defined herein, are as defined in the Benefits Agreement.
November 19, 2012 Julie Hambleton, M.D. [Home Address] Dear Julie, (January 22nd, 2014)
We are very pleased to extend to you an offer of employment with Five Prime Therapeutics, Inc. as a member of our Executive Committee with the title of Senior Vice President and Chief Medical Officer, reporting directly to me.